<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Leon, Martin B.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The PARTNER Trial: A New Paradigm for Treating Valvular Heart Disease</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">30-31</style></pages><abstract><style  face="normal" font="default" size="100%">The Placement of AoRTic TraNscathetER Valve [PARTNER] Trial showed for the first time that transcatheter aortic valve implantation (TAVI), when used in inoperable patients with severe symptomatic aortic stenosis, is life-saving and the best therapeutic option compared with standard medical therapy. In high-risk (but operable) patients, no outcome differences were noted between TAVI and surgical replacement of the aortic valve.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>